Results 61 to 70 of about 3,343,278 (165)
Movement Disorders in Developmental and Epileptic Encephalopathies
Abstract Background Monogenic developmental and epileptic encephalopathies (DEE) frequently feature co‐occurring movement disorders. Gene discovery has expanded epilepsy‐dyskinesia syndromes (EDS) from classic associations such as stereotypies in Rett syndrome to PRRT2‐related infantile seizures with paroxysmal dyskinesia and crouched gait in SCN1A ...
Shekeeb Mohammad +2 more
wiley +1 more source
Phenomenology of levodopa-induced dyskinesia
Levodopa has been effective against the motor features of Parkinson's disease for several decades. However, it is observed that long-term treatment with levodopa can be complicated by the development of various types of response fluctuations as well as ...
Samuel, Michael +3 more
core +1 more source
A serendipitous pharmacogenetic finding links the vulnerability to developing levodopa-induced dyskinesia to the age of onset of Huntington’s disease. Huntington’s disease is caused by a polyglutamate expansion of the protein huntingtin.
Svetlana A. Ivanova, Anton J. M. Loonen
doaj +1 more source
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño +6 more
wiley +1 more source
Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini +5 more
wiley +1 more source
Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for Parkinson's disease (PD). Using 7‐Tesla (7 T) MRI connectivity analysis to visualize the patient‐specific STN motor subdivision, we hypothesize that reprogramming patients who are stimulated outside of this subdivision can improve their ...
Yarit Wiggerts +6 more
wiley +1 more source
Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés +10 more
wiley +1 more source
Involvement of Autophagy in Levodopa‐Induced Dyskinesia
International audienceBackgroundAutophagy is intensively studied in cancer, metabolic and neurodegenerative diseases, but little is known about its role in pathological conditions linked to altered neurotransmission.
Benjamin Dehay +29 more
core +1 more source
Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
Dyskinesias represent a debilitating complication of levodopa therapy for Parkinson's disease (PD). While we recently demonstrated that levodopa-induced dyskinesia results from increased dopamine D1 receptor-mediated transmission, we also questioned the ...
Céline Guigoni +4 more
doaj +1 more source
Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye +9 more
wiley +1 more source

